PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment. The drug triggers the immune system to fight cancer.\<TAB\> Objective: To see if treatment with HAIPs to deliver liver-directed FUDR and Dexamethasone chemotherapy in combination with PDS01ADC is effective for certain cancers. Eligibility: People aged 18 and older who have cancer of the bile ducts that is only in the liver, or colorectal cancer that has spread to the liver, or cancer of the

Trial Details

NCT ID

NCT05286814

Phase

PHASE2

Sponsor

National Cancer Institute (NCI)

Status

RECRUITING

Cancer Type

Cholangiocarcinoma (Bile Duct) Liver Cancer

Interventions

• Dexamethasone
• PDS01ADC
• Intera 3000 Hepatic Artery Infusion Pump (HAIP)
• Floxuridine

Locations (sample)

• Bethesda, Maryland, United States|38.98067,-77.10026

Key Eligibility Criteria

• Inclusion Criteria- All Cohorts
• Participants must have a documented diagnosis of one of the following cancers:
• Metastatic colorectal cancer (mCRC)
• Intrahepatic cholangiocarcinoma (ICC)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cholangiocarcinoma (Bile Duct) Liver Cancer Trials on Trialify →